Exact Sciences nabs AbbVie executive to lead Cologuard — 4 insights

Abbvie's Vice President of U.S. Immunology Mark Stenhouse is joining Exact Sciences as president of the company's Cologuard product, effective April 2.

Here's what you should know.

1. At AbbVie, Mr. Stenhouse led the sales and marketing team for the company's anti-inflammatory drug Humira.

2. Humira has been the top-selling drug in the U.S. for five consecutive years. In 2017, it generated $18.4 billion in worldwide revenue.

3. Mr. Stenhouse worked his way up through AbbVie. He was hired as a field salesman nearly 30 years ago, rising through the rankings until he became VP of U.S. immunology.

4. On joining Exact Sciences, he said, "I view this as an opportunity to take a highly innovative screening test that fills an unmet healthcare need, and which has already undergone the most successful launch of any diagnostic product in history, to the next level. Exact Sciences truly captures it all — the highest quality science, committed people, and the value its products offer."

More articles on gastroenterology: 
UnitedHealth takes aim at Envision's ER billing practices through new website — 5 insights
Muve Health plans expansion to 30 facilities, plus 4 key quotes from CEO P. Marshall Maran
Wills Eye appeals to change classification from ASC to hospital: 4 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months